Glucagon-like Peptide 1 Receptor Agonist: Balancing Alarm and Caution

• References/Literatur

• 1 Hathaway JT, Shah MP, Hathaway DB. et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024; e242296
• 2 Lee MS, Grossman D, Arnold AC. et al. Incidence of nonarteritic anterior ischemic optic neuropathy: increased risk among diabetic patients. Ophthalmology 2011; 118: 959-963
• 3 Beri M, Klugman MR, Kohler JA. et al. Anterior ischemic optic neuropathy. VII. Incidence of bilaterality and various influencing factors. Ophthalmology 1987; 94: 1020-1028
• 4 Spital G, Faatz H. Diabetic Retinopathy – a Common Disease. Klin Monbl Augenheilkd 2023; 240: 1060-1070
• 5 Wai KM, Mishra K, Koo E. et al. Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study. Am J Ophthalmol 2024; 265: 39-47
• 6 Klonoff DC, Hui G, Gombar S. et al. Real-World Evidence Assessment of the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. J Diabetes Sci Technol
• 7 Bajka A, Bacci T, Wiest MRJ. et al. Feasibility and Clinical Utility of Wide-Field Optical Coherence Tomography Angiography Compared to Ultrawide-Field Fluorescein Angiography in Patients with Diabetic Retinopathy. Klin Monbl Augenheilkd 2023; 240: 490-495